BeiGene, Ltd. (NASDAQ:BGNE) Shares Sold by NINE MASTS CAPITAL Ltd

NINE MASTS CAPITAL Ltd lowered its position in BeiGene, Ltd. (NASDAQ:BGNE) by 17.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,700 shares of the company’s stock after selling 351 shares during the period. NINE MASTS CAPITAL Ltd’s holdings in BeiGene were worth $244,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BGNE. Capital International Investors increased its holdings in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after acquiring an additional 727,556 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after purchasing an additional 117,905 shares in the last quarter. Capital International Inc. CA increased its stake in shares of BeiGene by 6.0% during the 1st quarter. Capital International Inc. CA now owns 858,364 shares of the company’s stock worth $134,240,000 after purchasing an additional 48,615 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of BeiGene during the 4th quarter worth approximately $39,632,000. Finally, Goldman Sachs Group Inc. lifted its stake in BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after buying an additional 136,458 shares in the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeiGene Stock Up 6.8 %

Shares of NASDAQ:BGNE opened at $211.15 on Thursday. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $215.00. The stock’s 50-day moving average price is $173.90 and its two-hundred day moving average price is $162.68. The company has a current ratio of 1.98, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The firm has a market cap of $20.46 billion, a price-to-earnings ratio of -27.89 and a beta of 0.61.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The business had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same period last year, the company earned ($3.64) earnings per share. The company’s quarterly revenue was up 56.1% on a year-over-year basis. On average, research analysts forecast that BeiGene, Ltd. will post -5.13 EPS for the current year.

Insider Buying and Selling at BeiGene

In related news, insider Lai Wang sold 1,064 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $159.80, for a total value of $170,027.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Lai Wang sold 1,064 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $159.80, for a total transaction of $170,027.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Xiaobin Wu sold 5,556 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Insiders have sold a total of 13,210 shares of company stock worth $2,269,721 in the last quarter. 7.43% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on BGNE shares. Bank of America cut their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, Citigroup raised their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $237.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.